Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03070951 is registered in ClinicalTrials.gov with ObsEva SA as lead sponsor.

NCT NCT03070951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03070951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Lead sponsor
ObsEva SA
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2017
Completion date
October 4, 2020
Enrollment
511 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

heavy menstrual bleeding, uterine fibroids